#   Entity Extraction Example              #

## Response Object ##
## Entities ##
text:  b'Amgen Inc.'
type:  Company
relevance:  0.952124
sentiment:  positive
sentiment score: 0.0608422

text:  b'Amgen'
type:  Organization
relevance:  0.634637
sentiment:  negative
sentiment score: -0.487069

text:  b'Amgen of marketing Aranesp'
type:  JobTitle
relevance:  0.349249
sentiment:  negative
sentiment score: -0.479307

text:  b'FDA'
type:  Organization
relevance:  0.28342
sentiment:  negative
sentiment score: -0.240273

text:  b'etanercept'
type:  Drug
relevance:  0.236849
sentiment:  positive
sentiment score: 0.238926

text:  b'Xgeva'
type:  Company
relevance:  0.233277
sentiment:  negative
sentiment score: -0.245615

text:  b'Swedish Orphan Biovitrum'
type:  Company
relevance:  0.221792
sentiment:  negative
sentiment score: -0.412425

text:  b'Neupogen'
type:  Company
relevance:  0.217833
sentiment:  negative
sentiment score: -0.545041

text:  b'Los Angeles Times'
type:  PrintMedia
relevance:  0.21604
sentiment:  negative
sentiment score: -0.372585

text:  b'United Kingdom'
type:  Country
relevance:  0.201817
sentiment:  neutral

text:  b'Prolia'
type:  Company
relevance:  0.200038
sentiment:  neutral

text:  b'Kevin W. Sharer'
type:  Person
relevance:  0.194605
sentiment:  neutral

text:  b'Dezima Pharma'
type:  Company
relevance:  0.192527
sentiment:  positive
sentiment score: 0.25718

text:  b'Conejo Valley'
type:  GeographicFeature
relevance:  0.192107
sentiment:  neutral

text:  b'California'
type:  StateOrCounty
relevance:  0.191337
sentiment:  neutral

text:  b'Applied Molecular Genetics'
type:  PrintMedia
relevance:  0.191105
sentiment:  neutral

text:  b'Thousand Oaks'
type:  City
relevance:  0.189913
sentiment:  neutral

text:  b'chief executive officer'
type:  JobTitle
relevance:  0.188221
sentiment:  neutral

text:  b'febrile neutropenia'
type:  HealthCondition
relevance:  0.186178
sentiment:  negative
sentiment score: -0.519603

text:  b'president and chief executive officer'
type:  JobTitle
relevance:  0.182064
sentiment:  neutral

text:  b'George B. Rathmann'
type:  Person
relevance:  0.181358
sentiment:  neutral

text:  b'prostate cancer'
type:  HealthCondition
relevance:  0.17895
sentiment:  negative
sentiment score: -0.520006

text:  b'immune thrombocytopenic purpura'
type:  HealthCondition
relevance:  0.178191
sentiment:  negative
sentiment score: -0.642256

text:  b'biotechnology firm'
type:  FieldTerminology
relevance:  0.174712
sentiment:  positive
sentiment score: 0.324573

text:  b'official'
type:  JobTitle
relevance:  0.171261
sentiment:  neutral

text:  b'Robert A. Bradway'
type:  Person
relevance:  0.171209
sentiment:  neutral

text:  b'co-founder'
type:  JobTitle
relevance:  0.16963
sentiment:  neutral

text:  b'acute lymphoblastic leukemia'
type:  HealthCondition
relevance:  0.169119
sentiment:  negative
sentiment score: -0.214865

text:  b'Secondary hyperparathyroidism'
type:  HealthCondition
relevance:  0.167006
sentiment:  negative
sentiment score: -0.279464

text:  b'RA'
type:  Organization
relevance:  0.166148
sentiment:  neutral

text:  b'postmenopausal osteoporosis'
type:  HealthCondition
relevance:  0.16551
sentiment:  negative
sentiment score: -0.455022

text:  b'darbepoetin alfa'
type:  Drug
relevance:  0.165308
sentiment:  neutral

text:  b'Sensipar'
type:  City
relevance:  0.165189
sentiment:  negative
sentiment score: -0.382806

text:  b'oral mucositis'
type:  HealthCondition
relevance:  0.162129
sentiment:  neutral

text:  b'Johnson'
type:  Person
relevance:  0.161836
sentiment:  neutral

text:  b'Prolia'
type:  Person
relevance:  0.160641
sentiment:  negative
sentiment score: -0.425452

text:  b'Google Finance'
type:  Company
relevance:  0.160623
sentiment:  neutral

text:  b'spinal cord compression'
type:  HealthCondition
relevance:  0.160255
sentiment:  negative
sentiment score: -0.273586

text:  b'Neulasta'
type:  Person
relevance:  0.159769
sentiment:  neutral

text:  b'solid tumors'
type:  HealthCondition
relevance:  0.159764
sentiment:  negative
sentiment score: -0.273586

text:  b'Vectibix'
type:  Person
relevance:  0.15934
sentiment:  neutral

text:  b'Federal prosecutors'
type:  FieldTerminology
relevance:  0.15907
sentiment:  negative
sentiment score: -0.231843

text:  b'Blinatumomab'
type:  Drug
relevance:  0.159043
sentiment:  neutral

text:  b'National Institute of Clinical Excellence'
type:  Organization
relevance:  0.158851
sentiment:  neutral

text:  b'Romiplostim'
type:  Drug
relevance:  0.157352
sentiment:  neutral

text:  b'Hoechst Marion Roussel'
type:  Person
relevance:  0.157213
sentiment:  neutral

text:  b'Gordon M. Binder'
type:  Person
relevance:  0.157105
sentiment:  neutral

text:  b'Cinacalcet'
type:  Drug
relevance:  0.156729
sentiment:  neutral

text:  b'Xencor'
type:  Person
relevance:  0.156676
sentiment:  negative
sentiment score: -0.304764

text:  b'immune systems'
type:  FieldTerminology
relevance:  0.156544
sentiment:  negative
sentiment score: -0.570479



#   Keyword Extraction Example             #

## Response Object ##

## Keywords ##
text:  b'amgen'
relevance:  0.929011
sentiment:  negative
sentiment score: -0.282669

text:  b'word AMGen'
relevance:  0.764109
sentiment:  neutral

text:  b'Amgen Inc.'
relevance:  0.757484
sentiment:  negative
sentiment score: -0.216025

text:  b'Amgen\xe2\x80\x99s president'
relevance:  0.755975
sentiment:  neutral

text:  b'Amgen Acquires Dezima'
relevance:  0.730212
sentiment:  positive
sentiment score: 0.25718

text:  b'Swedish Orphan Biovitrum'
relevance:  0.701003
sentiment:  negative
sentiment score: -0.412425

text:  b'Amgen pleads'
relevance:  0.697239
sentiment:  negative
sentiment score: -0.830074

text:  b'Amgen bets'
relevance:  0.683402
sentiment:  neutral

text:  b'illegal marketing practices'
relevance:  0.682589
sentiment:  negative
sentiment score: -0.723758

text:  b'rheumatoid arthritis'
relevance:  0.655006
sentiment:  negative
sentiment score: -0.604623

text:  b'tumor necrosis factor'
relevance:  0.642708
sentiment:  negative
sentiment score: -0.733967

text:  b'Applied Molecular Genetics'
relevance:  0.631252
sentiment:  neutral

text:  b'Los Angeles Times'
relevance:  0.620231
sentiment:  negative
sentiment score: -0.372585

text:  b'chief executive officer'
relevance:  0.609278
sentiment:  neutral

text:  b'Granulocyte-Colony Stimulating Factor'
relevance:  0.59536
sentiment:  neutral

text:  b'rheumatoid arthritis drugs'
relevance:  0.571075
sentiment:  neutral

text:  b'anemia drug Aranesp'
relevance:  0.562614
sentiment:  negative
sentiment score: -0.830074

text:  b'closely related drugs'
relevance:  0.561966
sentiment:  negative
sentiment score: -0.484021

text:  b'multinational biopharmaceutical company'
relevance:  0.561675
sentiment:  neutral

text:  b'rheumatoid arthritis drug'
relevance:  0.549657
sentiment:  neutral

text:  b'disease-modifying anti-rheumatic drugs'
relevance:  0.549635
sentiment:  neutral

text:  b'certain HIV drugs'
relevance:  0.541611
sentiment:  negative
sentiment score: -0.53988

text:  b'News Release'
relevance:  0.540432
sentiment:  neutral

text:  b'cancer chemotherapy'
relevance:  0.539191
sentiment:  negative
sentiment score: -0.461929

text:  b'etanercept improved survival'
relevance:  0.539066
sentiment:  neutral

text:  b'necrosis factor blocker'
relevance:  0.534478
sentiment:  negative
sentiment score: -0.733967

text:  b'Company Profile Profile'
relevance:  0.533558
sentiment:  neutral

text:  b'Kevin W. Sharer'
relevance:  0.532941
sentiment:  neutral

text:  b'George B. Rathmann'
relevance:  0.530462
sentiment:  neutral

text:  b'FDA Approved Drug'
relevance:  0.529643
sentiment:  positive
sentiment score: 0.334308

text:  b'gastric cancer patients'
relevance:  0.529601
sentiment:  negative
sentiment score: -0.586591

text:  b'Robert A. Bradway'
relevance:  0.52708
sentiment:  neutral

text:  b'bone metastases'
relevance:  0.526714
sentiment:  negative
sentiment score: -0.273586

text:  b'clinical trials'
relevance:  0.526435
sentiment:  negative
sentiment score: -0.520006

text:  b'FDA approval'
relevance:  0.525455
sentiment:  negative
sentiment score: -0.570479

text:  b'necrosis factor alpha'
relevance:  0.524915
sentiment:  neutral

text:  b'initial public offering'
relevance:  0.52459
sentiment:  neutral

text:  b'major corporate acquisitions'
relevance:  0.524229
sentiment:  neutral

text:  b'fiscal cliff'
relevance:  0.521281
sentiment:  negative
sentiment score: -0.329845

text:  b'human erythropoetin product'
relevance:  0.520855
sentiment:  positive
sentiment score: 0.284829

text:  b'Gordon M. Binder'
relevance:  0.519878
sentiment:  neutral

text:  b'New York Times'
relevance:  0.516139
sentiment:  negative
sentiment score: -0.276884

text:  b'Dezima Pharma'
relevance:  0.515874
sentiment:  positive
sentiment score: 0.25718

text:  b'related whistleblower complaints'
relevance:  0.514445
sentiment:  negative
sentiment score: -0.571001

text:  b'kidney failure'
relevance:  0.514036
sentiment:  negative
sentiment score: -0.637671

text:  b'cancer-related bone injury'
relevance:  0.511232
sentiment:  negative
sentiment score: -0.245615

text:  b'PEG Granulocyte-Colony Stimulating'
relevance:  0.510084
sentiment:  neutral

text:  b'immune thrombocytopenic purpura'
relevance:  0.509515
sentiment:  negative
sentiment score: -0.642256

text:  b'candidate drug AMG'
relevance:  0.507354
sentiment:  negative
sentiment score: -0.423484

text:  b'marketing Aranesp'
relevance:  0.507305
sentiment:  neutral



#   Concept Tagging Example                #
## Object ##

## Concepts ##
text:  Amgen
relevance:  0.978435

text:  Etanercept
relevance:  0.457063

text:  Filgrastim
relevance:  0.434701

text:  Osteoporosis
relevance:  0.403637

text:  Oncology
relevance:  0.398445

text:  Rheumatoid arthritis
relevance:  0.379962

text:  Tumor necrosis factor-alpha
relevance:  0.37318

text:  Cancer
relevance:  0.366447



#   Sentiment Analysis Example             #

## Response Object ##

## Document Sentiment ##
type:  negative
score:  -0.397204


#   Title Extraction Example               #
Processing url:  https://en.wikipedia.org/wiki/Amgen

## Response Object ##

## Title ##
title:  b'Amgen - Wikipedia, the free encyclopedia'



#   Relation Extraction Example            #

## Object ##

## Relations ##
Subject:  b'AMGen (formerly Applied Molecular Genetics)'
Action:  b'is'
Object:  b'an American multinational biopharmaceutical company headquartered in Thousand Oaks, California'

Subject:  b'an American multinational biopharmaceutical company'
Action:  b'headquartered'

Subject:  b"the company's largest selling product lines"
Action:  b'were'
Object:  b'Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy'

Subject:  b'two closely related drugs'
Action:  b'to prevent'
Object:  b'infections in patients undergoing cancer chemotherapy'

Subject:  b'blocker'
Action:  b'used'

Subject:  b'Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA'
Action:  b'include'
Object:  b'Other products'

Subject:  b"the company's original name, Applied Molecular Genetics"
Action:  b'became'
Object:  b'the official name of the company in 1983 (three years'

Subject:  b"The company's first chief executive officer, from 1980,"
Action:  b'was'
Object:  b'co-founder George B. Rathmann'

Subject:  b'by Gordon M. Binder'
Action:  b'followed'

Subject:  b'by Kevin W. Sharer'
Action:  b'followed'
Object:  b'Robert A. Bradway became Amgen\xe2\x80\x99s president and chief executive officer'

Subject:  b'The company'
Action:  b'has'
Object:  b'made at least five major corporate acquisitions'

Subject:  b'The company'
Action:  b'has made'
Object:  b'at least five major corporate acquisitions'

Subject:  b'1989. Amgen'
Action:  b'received'
Object:  b'approval for the first recombinant human erythropoetin product, Epogen, for the treatment of anemia associated with chronic kidney failure'

Subject:  b'by Johnson and Johnson'
Action:  b'marketed'
Object:  b'Epogen'

Subject:  b'Epogen (also marketed by Johnson and Johnson under the tradename Procrit)'
Action:  b'be'
Object:  b'approved for anemia'

Subject:  b'Epogen (also marketed by Johnson and Johnson under the tradename Procrit)'
Action:  b'approved'
Object:  b'for anemia due to cancer chemotherapy, anemia due to treatment with certain HIV drugs'

Subject:  b'transfusions'
Action:  b'associated'
Object:  b'with surgery.'

Subject:  b'Amgen'
Action:  b'received'
Object:  b'FDA approval'

Subject:  b'A 2002 meta-analysis'
Action:  b'found'
Object:  b'that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%'

Subject:  b'the risk of documented infection'
Action:  b'reduced'
Object:  b'by 49%'

Subject:  b'by 49%'
Action:  b'documented'
Object:  b'infection'

Subject:  b'the risk of infection-related mortality'
Action:  b'reduced'
Object:  b'by 40%'

Subject:  b'2010 Amgen'
Action:  b'received'
Object:  b'FDA approval'

Subject:  b'Prolia'
Action:  b'reduced'
Object:  b'the rate of vertebral fractures'

Subject:  b'the FDA'
Action:  b'approved'
Object:  b'Xgeva for the prevention of complications of bone metastases in patients with solid tumors.[12] The clinical trials'

Subject:  b'The Los Angeles Times'
Action:  b'reported'
Object:  b'that AMGEN pled guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints'

Subject:  b'AMGEN'
Action:  b'agreed'
Object:  b'to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints'

Subject:  b'AMGEN'
Action:  b'agreed to pay'
Object:  b'$150 million in criminal penalty and $612 million'

Subject:  b'2012. Amgen'
Action:  b'paid'
Object:  b'$762 million'

Subject:  b'2012. Amgen'
Action:  b'pleading'
Object:  b'guilty'

Subject:  b'the fiscal cliff bill'
Action:  b'will allow'
Object:  b'to sell a class of drugs that includes Sensipar without government controls for an additional two years'

Subject:  b'the drugmaker'
Action:  b'to sell'
Object:  b'a class of drugs that includes Sensipar without government controls'

Subject:  b'Sensipar without government controls'
Action:  b'includes'
Object:  b'a class of drugs'

Subject:  b'The New York Times'
Action:  b'estimated'
Object:  b'that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million'

Subject:  b'the paragraph in the fiscal cliff bill'
Action:  b'will cost'
Object:  b'an estimated $500 million'

Subject:  b'other assessments'
Action:  b'concluded'
Object:  b'that the change would protect seniors in rural areas and reduce overall Medicare spending.[18] [19]'

Subject:  b'the change'
Action:  b'reduce'
Object:  b'overall Medicare spending.'

Subject:  b'2015. In September the company'
Action:  b'announced'
Object:  b'it would acquire Dezima Pharma for more than $1.55 billion.[20] The same day the company announced a collobaration with Xencor on 6 early stage immuno-oncology and inflammation programmes'

Subject:  b'Amgen'
Action:  b'will pay'
Object:  b'$45 million upfront'

Subject:  b'the deal'
Action:  b'being'
Object:  b'worth up to another $1.7 billion.[21] [22]'

Subject:  b'Amgen'
Action:  b'had'
Object:  b'twelve approved drugs or therapeutic biologicals for seventeen conditions (conditions lists are highly generalized'

Subject:  b'Epogen (Epoetin)'
Action:  b'also known'
Object:  b'as Procrit'

Subject:  b'Amgen'
Action:  b'had'
Object:  b'11 drugs in Phase III clinical trials.'

Subject:  b'the company'
Action:  b'announced'
Object:  b'it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.[45] Later in the same week, the company (in conjunction with AstraZeneca) reported positive results for brodalumab in a phase ||| trial comparing the compound with ustekinumab and a placebo in treating psoriasis.[46]'

Subject:  b'those'
Action:  b'took'
Object:  b'the compound'

Subject:  b'the company'
Action:  b'announced'
Object:  b'it would licence its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[47]'

Subject:  b'developer Celimmune'
Action:  b'plan'
Object:  b'to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[47]'

Subject:  b'developer Celimmune'
Action:  b'plan to develop'
Object:  b'the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[47]'

Subject:  b'the Fiscal Year'
Action:  b'Ended'

Subject:  b'FDA'
Action:  b'approves'
Object:  b'Xgeva'




#   Text Categorization Example            #

## Response Object ##

## Category ##
text:  health
score:  0.85



#   Microformats Parsing Example           #

## Response Object ##

## Microformats ##
Field:  b'RelLicense'
Data:  //en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License

Field:  b'FormattedName'
Data:  AMGen, Inc.

Field:  b'OrgName'
Data:  AMGen, Inc.

Field:  b'Url'
Data:  www.amgen.com



#   Taxonomy  Example                      #
## Response Object ##

## Categories ##
/health and fitness/disease/cancer  :  0.490817
/health and fitness/disease  :  0.457881
/news  :  0.434213



#   Combined  Example                      #
## Response Object ##

## Keywords ##
amgen  :  0.929011
word AMGen  :  0.764109
Amgen Inc.  :  0.757484
Amgen’s president  :  0.755975
Amgen Acquires Dezima  :  0.730212
Swedish Orphan Biovitrum  :  0.701003
Amgen pleads  :  0.697239
Amgen bets  :  0.683402
illegal marketing practices  :  0.682589
rheumatoid arthritis  :  0.655006
tumor necrosis factor  :  0.642708
Applied Molecular Genetics  :  0.631252
Los Angeles Times  :  0.620231
chief executive officer  :  0.609278
Granulocyte-Colony Stimulating Factor  :  0.59536
rheumatoid arthritis drugs  :  0.571075
anemia drug Aranesp  :  0.562614
closely related drugs  :  0.561966
multinational biopharmaceutical company  :  0.561675
rheumatoid arthritis drug  :  0.549657
disease-modifying anti-rheumatic drugs  :  0.549635
certain HIV drugs  :  0.541611
News Release  :  0.540432
cancer chemotherapy  :  0.539191
etanercept improved survival  :  0.539066
necrosis factor blocker  :  0.534478
Company Profile Profile  :  0.533558
Kevin W. Sharer  :  0.532941
George B. Rathmann  :  0.530462
FDA Approved Drug  :  0.529643

## Concepts ##
Amgen  :  0.978435
Etanercept  :  0.457063
Filgrastim  :  0.434701
Osteoporosis  :  0.403637
Oncology  :  0.398445
Rheumatoid arthritis  :  0.379962
Tumor necrosis factor-alpha  :  0.37318
Cancer  :  0.366447

## Entities ##
Company  :  Amgen Inc. ,  0.952124
Organization  :  Amgen ,  0.634637
JobTitle  :  Amgen of marketing Aranesp ,  0.349249
Organization  :  FDA ,  0.28342
Drug  :  etanercept ,  0.236849
Company  :  Xgeva ,  0.233277
Company  :  Swedish Orphan Biovitrum ,  0.221792
Company  :  Neupogen ,  0.217833
PrintMedia  :  Los Angeles Times ,  0.21604
Country  :  United Kingdom ,  0.201817
Company  :  Prolia ,  0.200038
Person  :  Kevin W. Sharer ,  0.194605
Company  :  Dezima Pharma ,  0.192527
GeographicFeature  :  Conejo Valley ,  0.192107
StateOrCounty  :  California ,  0.191337
PrintMedia  :  Applied Molecular Genetics ,  0.191105
City  :  Thousand Oaks ,  0.189913
JobTitle  :  chief executive officer ,  0.188221
HealthCondition  :  febrile neutropenia ,  0.186178
JobTitle  :  president and chief executive officer ,  0.182064
Person  :  George B. Rathmann ,  0.181358
HealthCondition  :  prostate cancer ,  0.17895
HealthCondition  :  immune thrombocytopenic purpura ,  0.178191
FieldTerminology  :  biotechnology firm ,  0.174712
JobTitle  :  official ,  0.171261
Person  :  Robert A. Bradway ,  0.171209
JobTitle  :  co-founder ,  0.16963
HealthCondition  :  acute lymphoblastic leukemia ,  0.169119
HealthCondition  :  Secondary hyperparathyroidism ,  0.167006
Organization  :  RA ,  0.166148


